Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

Classic hallucinogens such as LSD, psilocybin, DMT, and mescaline act primarily at the serotonin 2A (5HT2A) receptor and have seen a resurgence of research interest over the past two decades. Earlier clinical work from the 1950s–1970s and more recent pilot studies suggest potential therapeutic effects for conditions including addiction, anxiety, and depression, but the optimal way to integrate the acute psychedelic experience with disorder-specific psychotherapy remains unclear. Historical approaches ranged from repeated low-to-moderate dosing with psychodynamic work (psycholytic) to single high-dose sessions aimed at producing a peak or mystical experience (psychedelic model), and contemporary research requires models that marry pharmacology and psychosocial care within rigorous study designs and safety frameworks. Bogenschutz and Forcehimes set out to describe the rationale and development of a psychotherapeutic model tailored to psilocybin-assisted treatment of alcohol dependence. The paper outlines the historical context, reviews hypothesised biological and psychological mechanisms relevant to addiction, discusses the possible functions of psychotherapy in psychedelic treatment, and then presents a manualised, integrated model combining an alcohol-focused therapy (Motivational Enhancement and Taking Action, META), therapy aimed at preparation/support/integration for psychedelic sessions (PSI), and the psilocybin administrations themselves. The model has been implemented in a randomised, double-blind, controlled trial context and is intended both as a treatment manual for research and a starting point for future clinical use if efficacy is established.

The researchers describe a trial context in which psilocybin-assisted therapy for alcohol dependence is being evaluated in a randomised, double-blind, controlled trial (NCT02061293). The extracted text does not clearly report the sample size, recruitment setting, or detailed inclusion/exclusion criteria in this section, but indicates the population targeted is people with alcohol dependence and that psychosocial procedures are manualised for standardisation and fidelity monitoring. Intervention components are threefold: (1) an alcohol-specific psychotherapy called Motivational Enhancement and Taking Action (META), derived from Motivational Enhancement Therapy (MET) and Cognitive Behavioural Therapy (CBT); (2) Preparation, Support, and Integration (PSI), the set of sessions that prepare participants for, support them during, and help them integrate the psychedelic experience; and (3) the psychedelic medicine itself (psilocybin) or a control medication. META emphasises motivational interviewing initially, values clarification, goal setting, and a CBT-based STORC framework (Situations, Thoughts, Organic patterns, Responses, Consequences) with a workbook and modular strategy menus. PSI comprises multiple preparation sessions (two before the first drug session, one before the second and third), structured drug administration sessions, and debriefing/integration sessions (including a day-after debriefing and ongoing integration during later therapy visits). The drug administration protocol, as described, uses relatively high psilocybin doses in the range of 25 mg/70 kg to 40 mg/70 kg or control medication. During administrations participants typically wear eyeshades and listen to a standardised music programme; therapists conduct brief check-ins, offer non-directive support (reassurance, grounding, redirection) and monitor vital signs. A two-therapist dyad (ideally one female and one male) conducts the therapy, with both therapists attending drug sessions; substitutes are permitted only after at least two prior meetings. Safety measures include physician availability and emergency medications for severe hypertension, anxiety, or psychosis, although recent trials have seldom required these interventions. The extracted text does not provide details on statistical analysis plans, primary endpoints, timing of outcome assessments, or prespecified mediational analyses, beyond noting that manualisation, training, supervision, and fidelity monitoring are used to standardise psychosocial treatment.

Because the paper is primarily descriptive of a treatment model, direct outcome data from the current randomised trial are not reported in the extracted text. The authors do, however, summarise relevant findings from earlier clinical research and recent pilot studies that inform model development. A meta-analysis of six randomised trials of LSD for alcohol dependence (total n = 536) reported that LSD-treated participants were more likely to have abstinence or non-problematic drinking at the first post-treatment follow-up, with an odds ratio of 1.96 (95% CI [1.36, 2.84], p = .0003); beneficial effects persisted for up to 6 months in those studies. Recent pilot studies of psilocybin for nicotine dependence and for alcohol dependence have reported substantial decreases in target substance use, although the extracted text does not provide pooled effect sizes or controlled trial data for psilocybin. Evidence from those pilot studies links the intensity of subjective, mystical-type experiences during psilocybin sessions to better outcomes: participants who maintained abstinence in the smoking pilot had stronger mystical-type experiences, and in the alcohol pilot both mystical experience and broader intensity measures correlated with reductions in drinking. Neuroimaging studies conducted during acute psilocybin effects show decreased coupling within functional networks (for example, the default mode network), increased connectivity between networks, and associations between ego-dissolution experiences and decreased integrity of medial temporal and salience network connectivity. These acute brain changes have been proposed to relate to changes in affective processing (enhanced processing of positive stimuli and reduced processing of negative stimuli), which is relevant because negative affect predicts relapse in addiction. The authors note, however, that no published studies have yet documented persisting post-administration changes in human brain function. Basic mechanistic evidence from animal and molecular studies is summarised: classic hallucinogens act at 5HT2A receptors (which are downregulated after administration), and there is preliminary evidence for effects on neurotrophic factors such as BDNF and GDNF and on dendritic remodelling — all suggesting potential neuroplastic mechanisms that could support lasting behavioural change. Safety findings from recent clinical research indicate that psilocybin can be administered safely in controlled settings when appropriate screening, preparation, monitoring, and emergency plans are in place; the extracted text states emergency medications have rarely been required in recent trials. The authors also emphasise that controlled trials have not yet tested specific psychological mediators of therapeutic effect, so causal pathways linking subjective experience, neurobiology, and clinical outcomes remain speculative.

Bogenschutz and Forcehimes interpret the described therapy model as a practical, trial-adapted integration of disorder-specific psychotherapy and psychedelic-supportive work suited to a protocol of up to three relatively high-dose psilocybin sessions. They position the approach within historical practice (psychedelic and hybrid models used in mid-20th-century addiction treatment) while acknowledging alternative frameworks exist — for example, more frequent lower-dose (psycholytic-style) administrations or sacramental/long-term use patterns — and that different indications may require different formats. Since mechanisms of action are incompletely understood, the investigators chose a flexible, evidence-informed alcohol therapy (META) that is likely to be at least moderately effective on its own and could plausibly synergise with drug-induced change. In PSI they deliberately avoided prescribing particular subjective experiences, instead preparing participants for a broad range of possible effects. The authors argue that if future mechanistic research identifies critical pathways, psychosocial elements could be adapted to target those mechanisms more specifically and directive strategies could be tested. The discussion highlights pragmatic decisions and trade-offs embedded in the model. Using a therapist dyad provides additional in-session support and allows role separation between alcohol-focused and psychedelic-focused work, but increases therapist time and cost. Group therapy might offer mutual understanding and additional integration benefits not provided in dyadic formats, and the relative merits of role separation versus a single integrative therapist remain unresolved. The authors acknowledge multiple uncertainties: limited empirical data on how set and setting factors affect outcomes, the absence of controlled trials testing psychological mediators, and no clear evidence that the presented model is optimal. They call for prospective trials comparing different psychotherapeutic approaches, incorporation of mediational analyses in trial designs, and research into training and certification procedures should psychedelic-assisted treatments prove efficacious and move toward clinical adoption.

The authors conclude that psychedelic administrations can be integrated with evidence-based psychotherapy for alcoholism within clinical-trial settings, and that constructing such a coherent model requires many explicit decisions about therapist roles, session format, preparation, integration, and safety. They find the model they describe to be practical and feasible for research and potentially for clinical use if safety and efficacy are established, but they explicitly do not claim superiority of this model over alternatives. Finally, the authors emphasise the need for further research to understand mechanisms, to optimise psychotherapeutic components, and to develop training and certification procedures for clinicians who might provide psychedelic-assisted treatments in the future.